Entrada Therapeutics (TRDA) Operating Expenses (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Operating Expenses of $43.2 million for Q1 2026, up 1.96% year-over-year from $42.3 million in Q1 2025, and down 0.76% quarter-over-quarter from $43.5 million in Q4 2025.
Entrada Therapeutics (TRDA) Operating Expenses (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $43.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 1.96% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $184.1 million (up 9.54% YoY), while the FY2025 annual figure was $183.3 million, up 11.94% from the prior year.
- Operating Expenses for Q1 2026 stood at $43.2 million, down from $43.5 million in the prior quarter.
- The five-year high for Operating Expenses was $48.8 million in Q2 2025, with the low at $22.2 million in Q1 2022.
- The 5-year median for Operating Expenses is $38.0 million (2024), against an average of $36.5 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses jumped 163.92% in 2022, then grew 0.56% in 2025.
- Entrada Therapeutics' Operating Expenses stood at $25.6 million in 2022, then soared by 44.43% to $36.9 million in 2023, then gained by 17.11% to $43.3 million in 2024, then climbed by 0.56% to $43.5 million in 2025, then dropped by 0.76% to $43.2 million in 2026.
- Business Quant data shows TRDA's Operating Expenses at $43.2 million in Q1 2026, $43.5 million in Q4 2025, and $48.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 45.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.86 Mn |
| Mar 31, 2026 | 43.18 Mn |
| Dec 31, 2025 | 43.51 Mn |
| Sep 30, 2025 | 48.67 Mn |
| Jun 30, 2025 | 48.80 Mn |
| Mar 31, 2025 | 42.35 Mn |
| Dec 31, 2024 | 43.27 Mn |
| Sep 30, 2024 | 41.23 Mn |
| Jun 30, 2024 | 41.27 Mn |
| Mar 31, 2024 | 38.01 Mn |
| Dec 31, 2023 | 36.94 Mn |
| Sep 30, 2023 | 29.72 Mn |
| Jun 30, 2023 | 34.47 Mn |
| Mar 31, 2023 | 31.04 Mn |
| Dec 31, 2022 | 25.58 Mn |
| Sep 30, 2022 | 25.94 Mn |
| Jun 30, 2022 | 23.58 Mn |
| Mar 31, 2022 | 22.15 Mn |
| Dec 31, 2021 | 18.46 Mn |
| Sep 30, 2021 | 14.36 Mn |